Article
Immunology
Chen Yu, Ping Li, Xin Dang, Xuan Zhang, Yonghui Mao, Xiangmei Chen
Summary: This review focuses on lupus nephritis (LN), a common manifestation of systemic lupus erythematosus (SLE), and discusses the challenges in its diagnosis and treatment as well as the potential targets for future management.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Rheumatology
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H. Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M. Vital
Summary: Obinutuzumab appears to be effective and steroid-sparing in SLE patients with secondary non-response to rituximab.
Review
Medicine, Research & Experimental
Feigao Li, Wenyan Cui, Guangliang Huang, Yunfei Tian, Xinhui Zhang, Wenjuan He, Qian Sun, Xiaojuan Zhao, Yonghong Zhao, Dan Li, Xizhe Liu, Xiuju Liu
Summary: This study compared the clinical effectiveness and safety of novel biologics for the treatment of lupus nephritis using a reticulated meta-analysis approach. A total of 10 registered randomized controlled clinical trials involving 2148 subjects were included. The results showed that belimumab and obinutuzumab were the most effective in achieving complete and overall remission in the kidney.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Rheumatology
Renaud Felten, Marc Scherlinger, Philippe Mertz, Francois Chasset, Laurent Arnaud
Summary: Despite available therapies, persistently active and corticosteroid-dependent Systemic Lupus Erythematosus (SLE) represent a significant therapeutic challenge. This systematic review provides an updated view of targeted therapies currently in clinical development in SLE, with a special focus on the most promising ones.
Review
Multidisciplinary Sciences
Jaron Nazaroff, Sarah Oyadomari, Nolan Brown, Dean Wang
Summary: Most level I/II clinical studies on platelet-rich plasma (PRP) therapy focus on musculoskeletal injuries, with knee osteoarthritis and tendinopathy being the most commonly studied conditions. Inconsistent reporting of PRP composition exists among studies in different medical specialties, highlighting the need for standardized reporting in clinical research.
Review
Dermatology
Kareem G. Elhage, Raymond Zhao, Mio Nakamura
Summary: CLE and DM are autoimmune diseases with complex and difficult treatment options. Recent research suggests that JAK inhibitors, PDE-4 inhibitors, and biologics may be effective in reducing cutaneous symptoms of CLE and DM.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Yanfang Gao, Yuhan Wang, Rongshan Li, Xiaoshuang Zhou
Summary: The majority of clinical trials for lupus nephritis (LN) focus on the initial treatment of adult proliferative LN, with most trials being small-scale, short-term, randomized, parallel-assigned, and inadequately masked interventional trials with diverse eligibility criteria and outcome measures.
FRONTIERS IN MEDICINE
(2021)
Review
Immunology
Peng Cao, Wenjing Xu, Shuyi Jiang, Litao Zhang
Summary: Dupilumab shows clear effectiveness and safety in the treatment of prurigo nodularis, as evidenced by a systematic review of multiple studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Peng Cao, Wenjing Xu, Litao Zhang
Summary: Rituximab, omalizumab, and dupilumab have similar clinical benefits for patients with bullous pemphigoid, but rituximab leads to higher recurrence rates, adverse events, and mortality rates.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Allergy
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, Jonas Binnmyr, Knut Brockow, Alan D. Irvine, Susanne Halken, Charlotte G. Mortz, Carsten Flohr, Peter Schmid-Grendelmeier, Lauri-Ann Van der Poel, Antonella Muraro, Stephan Weidinger, Thomas Werfel, Jochen Schmitt
Summary: This study critically evaluated systemic treatments for moderate-to-severe AD, with the most reliable and safe trial evidence found for the use of dupilumab in adults for up to 1 year. Limited evidence-based conclusions were drawn for other systemic treatments due to methodological restrictions. Therefore, head-to-head trials with novel systemic treatments are needed to clarify the future role of conventional therapies.
Review
Chemistry, Medicinal
Milton Arias, Henry Oliveros, Sharon Lechtig, Rosa-Helena Bustos
Summary: This systematic review reevaluated the evidence of using biologics as treatment options for severe and advanced COVID-19. The study identified IL6 and IL1 inhibitors, interferons, mesenchymal stem cells treatment, and anti-spike antibodies as popular targets. The efficacy of these treatments was inconclusive except for some studies on anti-spike antibodies. However, I16 and IL1 inhibitors as well as interferons showed promising data, indicating a need for further studies.
Review
Chemistry, Analytical
Ratih Ratih, Mufarreh Asmari, Ahmed M. Abdel-Megied, Fawzy Elbarbry, Sami El Deeb
Summary: Biologics have complex production processes and face various challenges, including similarity testing and international regulatory guidelines. Since 2006, biosimilars have entered the biotechnology arena with intense competition.
MICROCHEMICAL JOURNAL
(2021)
Review
Medicine, Research & Experimental
Wenyan Cui, Yunfei Tian, Guangliang Huang, Xinhui Zhang, Feigao Li, Xiuju Liu
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by loss of immune tolerance. Lupus nephritis (LN) is a common manifestation of severe organ damage in SLE, and an important cause of disability and death. Traditional immunosuppressive therapy has limitations, and targeted therapies with novel biologics have emerged. This review summarizes the pathogenesis of LN, mechanisms of biological targets, and analyzes clinical trials of new biologics for treating LN. Lessons from these trials can guide future trial programs for better treatment approaches.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Laura Macca, Vittoria Moscatt, Manuela Ceccarelli, Ylenia Ingrasciotta, Giuseppe Nunnari, Claudio Guarneri
Summary: Hidradenitis suppurativa (HS) is associated with human immunodeficiency virus (HIV), and HIV-infected individuals are more susceptible to developing HS, particularly in atypical sites due to HIV-related immunosuppression.
Article
Rheumatology
Laura Chadwick, Lianne Kearsley-Fleet, Nina Brown, Kath D. Watson, Mark Lunt, Deborah P. M. Symmons, Kimme L. Hyrich
Editorial Material
Rheumatology
Marwan Bukhari, Alison Kent
Letter
Rheumatology
Anastasia-Vasiliki Madenidou, Marwan Bukhari
Editorial Material
Rheumatology
David Walker, Ade Adebajo, Marwan Bukhari
Editorial Material
Rheumatology
Mark D. Russell, Marwan Bukhari, Ajay M. Shah, James B. Galloway
Editorial Material
Rheumatology
James Galloway, Marwan Bukhari
Editorial Material
Rheumatology
Imran H. Yusuf, Marwan Bukhari, James Galloway, Andrew J. Lotery
Article
Medicine, General & Internal
Peter W. Horby, Martin J. Landray
Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.
Editorial Material
Rheumatology
Marwan Bukhari, Sandra Robinson, Ade Adebajo, Peta Heslop, David Walker
Article
Rheumatology
Katie Bechman, Kapil Halai, Mark Yates, Sam Norton, Andrew P. Cope, Kimme L. Hyrich, James B. Galloway
Summary: This study aimed to describe the frequency and predictors of nonserious infections (NSI) in rheumatoid arthritis patients, as well as to compare the incidence of NSI across different biologic agents. The results showed that all biologics were associated with a greater risk of NSI, with significant differences observed between agents.
ARTHRITIS & RHEUMATOLOGY
(2021)
Editorial Material
Rheumatology
Katie Bechman, Mrinalini Dey, Mark Yates, Marwan Bukhari, Kevin Winthrop, James B. Galloway
JOURNAL OF RHEUMATOLOGY
(2021)
Review
Rheumatology
Peter C. Taylor, Matthew Woods, Catherine Rycroft, Priya Patel, Sophee Blanthorn-Hazell, Toby Kent, Marwan Bukhari
Summary: The research revealed limited evidence on the quality of life, burden, and treatment patterns of patients with moderate RA in the UK, showing that these patients face significant disability burden and dissatisfaction with current treatments. NICE in the UK has not approved advanced therapies for moderate RA patients, restricting their treatment options.
Article
Medicine, General & Internal
Peter W. Horby, Guilherme Pessoa-Amorim, Natalie Staplin, Jonathan R. Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J. Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J. Kenneth Baillie, Buddha Basnyat, Maya H. Buch, Lucy C. Chappell, Jeremy Day, Saul N. Faust, Raph L. Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray
Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.
Article
Critical Care Medicine
Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L. Goodman, Pauline A. Swift, Sankarasubramanian Rajaram, Alison Graves-Jones, Jonathan Edelman, Fiona Burns, Angela M. Minassian, Iksung Cho, Lakshmi Kumar, Joyce S. Plested, E. Joy Rivers, Andreana Robertson, Filip Dubovsky, Greg Glenn, Paul T. Heath
Summary: This study reports the safety, immunogenicity, and efficacy profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines. The results suggest that simultaneous vaccination might be a viable immunization strategy.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Medicine, General & Internal
Peter W. Horby, Martin J. Landray
Summary: Tocilizumab improved survival and other clinical outcomes in hospitalized COVID-19 patients with hypoxia and systemic inflammation, regardless of the level of respiratory support, and provided additional benefits on top of systemic corticosteroid therapy.
